Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2014年 / 12卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [41] Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+mature T-cell lymphomas (MTCL).
    O'Connor, Owen A.
    Pro, Barbara
    Illidge, Tim
    Trumper, Lorenz H.
    Larsen, Emily K.
    Manley, Thomas John
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+mature T-cell lymphomas (MTCL).
    O'Connor, Owen A.
    Pro, Barbara
    Illidge, Tim
    Trumper, Lorenz H.
    Larsen, Emily K.
    Kennedy, Dana A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Dominance of Nonmalignant T-Cell Clones and Distortion of the TCR Repertoire in the Peripheral Blood of Patients with Cutaneous CD30+ Lymphoproliferative Disorders
    Humme, Daniel
    Lukowsky, Ansgar
    Steinhoff, Matthias
    Beyer, Marc
    Walden, Peter
    Sterry, Wolfram
    Assaf, Chalid
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (01) : 89 - 98
  • [44] Interferon-γCutaneous CD8+ CD30+ T-cell lymphoproliferative disorder: case report
    Reactions Weekly, 2021, 1859 (1) : 194 - 194
  • [45] QuPath Analysis for CD30+ Cutaneous T-Cell Lymphoma
    Cieslak, Cassandra
    Mitteldorf, Christina
    Kroemer-Olbrisch, Tanja
    Kempf, Werner
    Stadler, Rudolf
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2023, 45 (02) : 93 - 98
  • [46] Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+mature T-cell lymphomas (MTCL)
    O'Connor, Owen A.
    Pro, Barbara
    Illidge, Tim
    Trumper, Lorenz H.
    Larsen, Emily K.
    Kennedy, Dana A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Use of brentuximab vedotin for recalcitrant CD30+cutaneous T cell lymphoma
    Freeman, E. E.
    Tawa, M.
    Dorosario, A. A.
    Kupper, T. S.
    Fisher, D. C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 : S94 - S94
  • [48] CD30-Positive Cutaneous T-Cell Lymphoma and Response to Brentuximab Vedotin: 2 Illustrative Cases
    Mody, Kabir
    Wallace, Jill S.
    Stearns, Diane M.
    Bowers, George
    Lacy, Shannon R.
    Levy, Norman B.
    Zug, Kathryn A.
    Lansigan, Frederick
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (03): : 319 - 323
  • [49] Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas
    Hasegawa, Gen
    Nakagawa, Noriharu
    Ueda, Yoshimichi
    Yamazaki, Masahide
    LEUKEMIA RESEARCH REPORTS, 2025, 23
  • [50] Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management
    Scarisbrick, Julia J.
    FUTURE ONCOLOGY, 2017, 13 (27) : 2405 - 2411
12345